摘要
目的评价特异性免疫治疗变应性鼻炎的疗效及安全性。方法对65例变应性鼻炎患者进行1～3年特异性免疫治疗后,通过患者的症状评估进行临床疗效及安全性的分析。结果 65例患者中3例中途退出(治疗未满1年),其余62例经过1～3年特异性免疫治疗,多数患者症状均有不同程度好转。治疗结束时显效25例(40.32%),有效18例(29.03%),无效19例(30.65%),总有效率69.35%。其中25例治疗满1年,显效7例(28%),有效7例(28%),无效11例(44%),有效率56%;2 1例满2年,显效1 0例(4 7.6 2%),有效5例(2 3.8 1%),无效6例(2 8.5 7%),有效率7 1.4 3%;1 6例满3年,显效8例(5 0%),有效6例(3 7.5%),无效2例(1 2.5%),有效率8 7.5%。所有患者均未发生严重不良反应。结论特异性免疫治疗对于变应原明确的变应性鼻炎患者,是一种有效、安全可靠的治疗方法。
Objective To evaluate the efficacy and safety of specific immunotherapy for patients with allergic rhinitis. Methods 65 patients with allergic rhinitis received the specific immunotherapy for 1 ~ 3 years. Symptom scores were used for evaluating the efficacy and safety of immunotherapy. Results Of 65 patients, 3 quitted. Majority of the other 62 patients got better after treatment. 25 patients （40.32%） got obvious improvement, 18 （29.03%） were effective, and 19 （30.65%） were ineffective. The total effective rate was 69.35%. Of 25 patients received treatment for one year, 7 （28%） were obvious effective, 7 were （28%） effective, with an effective rate of 56%. Of 21 patients received treatment for two years, 10 （47.62%） were obvious effective, 5 （ 23.81% ） were effective, with an effeetive rate of 71.43 % . Of 16 patients received treatment for three years, 8 （50%） were obvious effective, 6 （37.5%） were effective, with an effective rate of 87.5%. No serious adverse reaction occurred. Conclusion Specific immunotherapy is an effective and safe treatment method for patients with allergic rhinifis.
出处
《中国耳鼻咽喉颅底外科杂志》
CAS
2012年第6期466-468,共3页
Chinese Journal of Otorhinolaryngology-skull Base Surgery
